Sagimet Biosciences Inc Series A (SGMT)

$8.72 +1.68 (23.86%)
Market Cap 267.49M
Revenue (ttm) 0.00
Net Income (ttm) -45.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 2,010,300
Avg Vol 1,590,086
Day's Range N/A - N/A
Shares Out 30.68M
Stochastic %K 80%
Beta 2.21
Analysts Strong Sell
Price Target $27.57

Company Profile

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 561 8600
Address:
155 Bovet Road, Suite 303, San Mateo, United States
John___wick44
John___wick44 Jun. 21 at 7:34 PM
$SGMT BO 38 minimum
0 · Reply
Dark_Horse_Investments
Dark_Horse_Investments Jun. 20 at 8:43 PM
$SGMT this has to rally to $400M - $500M market cap by end of year... Phase 1 of acne TVB-3567 should be nearly completed, investors will get a highlight of data and company move into phase 2 for early 2026 (12 week). Full data on phase 1 will be out in 2026. Data and valuation will lead to capital raise for MASH. This will beat out ALL competition in MASH even addressing F4. Expect a rocky road, ups and downs but FASN inhibitors are very powerful technologies.
0 · Reply
shibadad
shibadad Jun. 20 at 8:16 PM
$SGMT While not the highest intraday high, this is the highest close since the acne data dropped. Decent volume with a strong finish on a summer Friday. Bodes well for Monday. This could double from here and still be arguably undervalued.
0 · Reply
Bullish_Swagger
Bullish_Swagger Jun. 20 at 8:02 PM
$GCTK - $SGMT - $AISP - New swing going into the weekend - Stay safe - Pray for 0 wars - Love thy neighbor- ❤️
2 · Reply
norbertm
norbertm Jun. 20 at 7:56 PM
$SGMT Push!!!
0 · Reply
ASKING7
ASKING7 Jun. 20 at 7:28 PM
$SGMT only thing I want to say is check the volume and ask yourself why
1 · Reply
Catmando3
Catmando3 Jun. 20 at 7:25 PM
$SGMT FML I’m up 6k today. Take profits or yolo!?!?!?!? Ahhhh i can’t decide.
2 · Reply
perpetbill
perpetbill Jun. 20 at 7:17 PM
$SGMT going straight up
0 · Reply
GSP
GSP Jun. 20 at 6:56 PM
$SGMT nice turn back up today. .
0 · Reply
Rikilk
Rikilk Jun. 20 at 6:50 PM
$SGMT Bears... where are you now?
0 · Reply
Latest News on SGMT
Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025

Jun 9, 2025, 7:00 AM EDT - 12 days ago

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025

Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567

Jun 4, 2025, 1:45 PM EDT - 17 days ago

Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis

Jun 4, 2025, 5:00 AM EDT - 17 days ago

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis

Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025

May 22, 2025, 8:00 AM EDT - 4 weeks ago

Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025

Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 8, 2025, 6:00 AM EDT - 6 weeks ago

Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates

Mar 12, 2025, 7:30 AM EDT - 3 months ago

Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne

Mar 11, 2025, 8:00 AM EDT - 3 months ago

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne

Sagimet Biosciences' Denifanstat Should Be Worth More Today

Mar 7, 2025, 4:27 PM EST - 3 months ago

Sagimet Biosciences' Denifanstat Should Be Worth More Today

Sagimet: More Than Just A MASH Drug Development Biotech

Nov 14, 2024, 3:56 PM EST - 7 months ago

Sagimet: More Than Just A MASH Drug Development Biotech

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

Nov 12, 2024, 6:30 AM EST - 7 months ago

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat

Oct 18, 2024, 3:10 PM EDT - 8 months ago

Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

Oct 11, 2024, 7:00 AM EDT - 9 months ago

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

Oct 1, 2024, 7:00 AM EDT - 9 months ago

Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 1, 2024, 12:05 AM EDT - 9 months ago

Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

Sep 12, 2024, 7:30 AM EDT - 10 months ago

Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

Aug 1, 2024, 8:00 AM EDT - 11 months ago

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide

Jul 31, 2024, 12:24 PM EDT - 11 months ago

Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide

Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

Jun 6, 2024, 5:00 AM EDT - 1 year ago

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

May 16, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

May 15, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

May 7, 2024, 8:00 AM EDT - 1 year ago

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

May 6, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity

Apr 26, 2024, 12:23 PM EDT - 1 year ago

Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

Apr 22, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

Mar 27, 2024, 4:01 PM EDT - 1 year ago

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

Mar 25, 2024, 7:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Mar 25, 2024, 6:15 AM EDT - 1 year ago

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

Feb 29, 2024, 8:00 AM EST - 1 year ago

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock

Jan 25, 2024, 8:58 PM EST - 1 year ago

Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock

Sagimet: Additional Upside Possible After Latest NASH Data Release

Jan 24, 2024, 1:55 PM EST - 1 year ago

Sagimet: Additional Upside Possible After Latest NASH Data Release

Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock

Jan 23, 2024, 5:45 PM EST - 1 year ago

Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock

Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Jan 22, 2024, 11:10 PM EST - 1 year ago

Gannex's Strategic Partner Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Jan 22, 2024, 7:00 AM EST - 1 year ago

Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic

Dec 4, 2023, 8:00 AM EST - 1 year ago

Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic

Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit

Nov 28, 2023, 8:00 AM EST - 1 year ago

Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit

Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 22, 2023, 8:00 AM EST - 1 year ago

Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference

Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Nov 13, 2023, 8:00 AM EST - 1 year ago

Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates

Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023

Nov 10, 2023, 8:30 AM EST - 1 year ago

Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023

Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023

Oct 24, 2023, 11:00 AM EDT - 1 year ago

Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023

Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference

Oct 18, 2023, 4:05 PM EDT - 1 year ago

Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference

Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

Sep 27, 2023, 4:05 PM EDT - 1 year ago

Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma

Sagimet Biosciences: Recent IPO With Emerging Positive Data In NASH

Sep 27, 2023, 2:48 PM EDT - 1 year ago

Sagimet Biosciences: Recent IPO With Emerging Positive Data In NASH

Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

Aug 21, 2023, 4:02 PM EDT - 1 year ago

Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

Sagimet Biosciences Announces Closing of Underwriters' Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public Offering

Aug 15, 2023, 4:04 PM EDT - 2 years ago

Sagimet Biosciences Announces Closing of Underwriters' Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public Offering

Sagimet Biosciences Announces Leadership Changes

Jul 20, 2023, 4:05 PM EDT - 2 years ago

Sagimet Biosciences Announces Leadership Changes

U.S. IPO Weekly Recap: July IPO Market Kicks Off With Sizable Biotechs

Jul 15, 2023, 3:28 AM EDT - 2 years ago

U.S. IPO Weekly Recap: July IPO Market Kicks Off With Sizable Biotechs

APGE ODD OPHV SRFM TURB

Sagimet Biosciences Announces Pricing of Upsized Initial Public Offering

Jul 13, 2023, 9:10 PM EDT - 2 years ago

Sagimet Biosciences Announces Pricing of Upsized Initial Public Offering

IPO Update: Sagimet Biosciences Pushes Forward On IPO Plan

Jul 11, 2023, 5:41 PM EDT - 2 years ago

IPO Update: Sagimet Biosciences Pushes Forward On IPO Plan

Sagimet Biosciences sets IPO terms, to raise up to about $80 million

Jul 10, 2023, 7:05 AM EDT - 2 years ago

Sagimet Biosciences sets IPO terms, to raise up to about $80 million

John___wick44
John___wick44 Jun. 21 at 7:34 PM
$SGMT BO 38 minimum
0 · Reply
Dark_Horse_Investments
Dark_Horse_Investments Jun. 20 at 8:43 PM
$SGMT this has to rally to $400M - $500M market cap by end of year... Phase 1 of acne TVB-3567 should be nearly completed, investors will get a highlight of data and company move into phase 2 for early 2026 (12 week). Full data on phase 1 will be out in 2026. Data and valuation will lead to capital raise for MASH. This will beat out ALL competition in MASH even addressing F4. Expect a rocky road, ups and downs but FASN inhibitors are very powerful technologies.
0 · Reply
shibadad
shibadad Jun. 20 at 8:16 PM
$SGMT While not the highest intraday high, this is the highest close since the acne data dropped. Decent volume with a strong finish on a summer Friday. Bodes well for Monday. This could double from here and still be arguably undervalued.
0 · Reply
Bullish_Swagger
Bullish_Swagger Jun. 20 at 8:02 PM
$GCTK - $SGMT - $AISP - New swing going into the weekend - Stay safe - Pray for 0 wars - Love thy neighbor- ❤️
2 · Reply
norbertm
norbertm Jun. 20 at 7:56 PM
$SGMT Push!!!
0 · Reply
ASKING7
ASKING7 Jun. 20 at 7:28 PM
$SGMT only thing I want to say is check the volume and ask yourself why
1 · Reply
Catmando3
Catmando3 Jun. 20 at 7:25 PM
$SGMT FML I’m up 6k today. Take profits or yolo!?!?!?!? Ahhhh i can’t decide.
2 · Reply
perpetbill
perpetbill Jun. 20 at 7:17 PM
$SGMT going straight up
0 · Reply
GSP
GSP Jun. 20 at 6:56 PM
$SGMT nice turn back up today. .
0 · Reply
Rikilk
Rikilk Jun. 20 at 6:50 PM
$SGMT Bears... where are you now?
0 · Reply
spirituallyconsistenttp
spirituallyconsistenttp Jun. 20 at 6:46 PM
$SGMT I've been telling you all to load up on SGMT from below 2. Next week we enter double-digits nicely!
0 · Reply
biostock
biostock Jun. 20 at 6:09 PM
$SGMT Squeeze em. Send it to 10 $SPY $QQQ
1 · Reply
John_week
John_week Jun. 20 at 5:47 PM
$SGMT strong af
1 · Reply
aquira
aquira Jun. 20 at 3:08 PM
$BMEA $MODV $AGL $RCKT $SGMT fecckkkkk 17k gains on these tickers just evaporated. Should've sold all of them early last week. Now I'm in the red in all of these.
1 · Reply
ontariomark
ontariomark Jun. 20 at 2:59 PM
$AIFF I'm hoping something similar will happen as did with $SGMT. They released amazing news overnight recently and overnight prices skyrocketed. Then during market hours prices dropped for a few days. Right when a lot of people were giving up hope, the price flew up a few days later and climbed aggressively for a few days. Monitoring
2 · Reply
himsssss
himsssss Jun. 20 at 2:04 PM
$SGMT if it base at $8 for a little bit, its going to get explosive.
0 · Reply
cats44ever
cats44ever Jun. 20 at 1:50 PM
$SGMT Any more analyst stock price adjustments besides Jones?
2 · Reply
himsssss
himsssss Jun. 20 at 1:38 PM
$SGMT well that dip did not last long at all LOL
0 · Reply
John_week
John_week Jun. 20 at 1:34 PM
$SGMT
0 · Reply
John_week
John_week Jun. 20 at 1:33 PM
$SGMT
0 · Reply
BearTamerTrading
BearTamerTrading Jun. 20 at 12:05 AM
$KNW $PRSO $SGMT $ILLR If you’re tired of missing plays, subscribe to my YouTube channel for live trading alerts starting daily at 6:00 AM: youtube.com/@beartamertrading It’s 100% free—no gimmicks, no scams. Just a community focused on helping retail traders grow. Let’s build your account together. See you at 6 AM!
0 · Reply
dallas75
dallas75 Jun. 19 at 6:09 PM
$SGMT let's go
0 · Reply